DP
UNCY icon

Diadema Partners’s Unicycive Therapeutics UNCY Stock Holding History

Diadema Partners’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$698K Buy
+106,083
New +$695K 0.12% 99

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Diadema Partners's UNCY Position: Q1 2026 in Review

Diadema Partners opened a new position in Unicycive Therapeutics (UNCY) in Q1 2026: 106,083 shares worth $698K. The stake represents 0.12% of the portfolio and ranks #99 among its holdings.

51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Diadema Partners held 106,083 shares of Unicycive Therapeutics worth $698K as of Q1 2026.
  • Unicycive Therapeutics was a new Diadema Partners position in Q1 2026.
  • Unicycive Therapeutics made up 0.12% of Diadema Partners's portfolio in Q1 2026, its #99 holding.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.